BOQI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the
“Company”), a leading healthcare products and services provider in
China, today announced its financial results for the first quarter
ended March 31, 2021.
First Quarter 2021 Financial Highlights
- Revenues grew by
$1.75 million, or by 423%, to $2.17 million for the first quarter
of 2021 from $0.41 million in the same period of 2020.
- Gross profit
increased by $0.51 million, or by 620%, to $0.59 million for the
first quarter 2021 from $0.08 million in the same period of
2020.
- Gross margin increased to 27.32% for the first
quarter 2021 from 19.84% in the same period of 2020.
|
|
For three months ended March 31 |
|
Differences
due to rounding |
|
|
2021 |
|
|
|
2020 |
|
|
|
% change |
|
Revenues |
|
$ |
2.17 million |
|
|
$ |
0.41 million |
|
|
|
423 |
% |
Gross
profit |
|
$ |
0.59 million |
|
|
$ |
0.08 million |
|
|
|
620 |
% |
Gross
margin |
|
|
27.32 |
% |
|
|
19.85 |
% |
|
|
7.47 |
% |
Net loss
from continuing operations |
|
$ |
3.29 million |
|
|
$ |
1.35 million |
|
|
|
144 |
% |
Net loss
attributable to BOQI International Medical Inc. |
|
$ |
3.33 million |
|
|
$ |
2.19 million |
|
|
|
52 |
% |
Mr. Tiewei Song, Chief Executive Officer and
President of the Company, commented: “We are pleased to see both of
our revenues and gross margins continued to be boosted by our
expanded business operations and enhanced efficiency during the
first quarter of 2021. These improvements support our strategy to
build a comprehensive healthcare ecosystem in China with a focus on
a high-end gynecology-focused hospital chain through both organic
growth and bolt-on acquisition opportunities. We intend to maintain
this momentum in order to achieve sustainable profitability and
create value for our shareholders.”
Revenues
Revenues for the three months ended March 31,
2021 and 2020 were $2.17 million and $0.41 million, respectively.
Compared with the same period in 2020, revenue in the 2021 period
increased by $1.75 million, or 423%, mainly due to the increase in
sales of wholesale pharmaceuticals of $1.10 million and medical
services of $0.70 million.
Revenues from the retail pharmacy segment for
the three months ended March 31, 2021 was $0.12 million, generated
from 5 retail pharmacy stores in Chongqing.
Revenues from wholesale medical devices segment
for the three months ended March 31, 2021 and 2020 were $0.06
million and $0.25 million, respectively. The decrease is mainly due
to low demand for medical devices during the first quarter, which
is typical because of the long break during the Chinese New
Year.
Cost of revenues
Cost of revenues for the three months ended
March 31, 2021 and 2020 was $1.58 million and $0.33 million,
respectively. The Company recorded an obsolescence loss of $0.03
million with respect to inventories, which was included in the cost
of revenues for the three months ended March 31, 2021 compared with
an obsolescence loss of $0.30 million for the same period in 2020.
The decrease of inventory provision is due to the obsolescence of
inventory held for sale by the Boqi pharmacies in Dalian, whose
stores suffered from the lockdown policy in effect due to the
COVID-19 pandemic.
Gross profit
Gross profit for the three months ended March
31, 2021 and 2020 was $0.59 million and $0.08 million,
respectively. For the three months ended March 31, 2021 and 2020,
we had a gross margin of 27.32% and 19.85%, respectively. For the
three months ended March 31, 2021 and 2020, the gross profit margin
of our: (i) retail pharmacy segment were 17.17% in 2021; (ii)
wholesale medical devices segment were 52.73% and 19.73%,
respectively; (iii) wholesale pharmaceuticals segments were 36.21%
and 19.99%, respectively; and (iv) medical services segment was
9.32% for the three months ended March 31, 2021.
Operating expenses
Operating expenses from continuing operations
were $3.83 million for the three months ended March 31, 2021 as
compared to $1.41 million for the same period in 2020, an increase
of $2.43 million or 173%. The increase is primarily attributable to
the inclusion of the operating expenses of the medical services
segment of appropriately $0.32 million and the Chongqing Guanzan
Technology Co., Ltd. (“Guanzan Group”) of approximately $0.51
million, which we acquired in March 2020, and the amortization of
the discount relating to the convertible notes issued in 2021 of
$1.61 million, and general operating expenses which primarily
include legal expenses of $0.28 million and audit fee of $0.15
million and other compliance expense.
Other expenses
For the three months ended March 31, 2021 and
2020, we reported other expenses of $0.03 million and $0.02
million, respectively. Other expenses mainly consisted of interest
expense relating to the bank loans of the Guanzan Group, Chongqing
Guoyitang Hospital Co., Ltd. (“Guoyitang”) and Chaohu Zhongshan
Minimally Invasive Hospital (“Zhongshan”). The Company completed
the acquisitions of Guoyitang and Zhongshan in February, 2021.
Net loss from continuing operation
Net loss from continuing operations was $3.29
million and $1.35 million for the three months ended March 31, 2021
and 2020, respectively. The increase was primarily due to the
increase in operating expenses and the other expenses described
above.
Net loss attributable to BOQI International
Medical Inc.
As a result of the foregoing our net loss
attributable to BOQI International Medical Inc. increased by $1.14
million to $3.33 million for the three months ended March 31, 2021
from $2.19 million for the three months ended March 31, 2020.
Cash and working capital
As of March 31, 2021, we had cash of $2.84
million and negative working capital of $0.18 million as compared
to cash of $0.14 million and working capital of $9.62 million as of
December 31, 2020.
About BOQI International Medical
Inc.
BOQI International Medical Inc. was founded in
2006. In February 2019, the Board of Directors of the Company
determined to focus on the healthcare industry. The Company is now
exclusively a healthcare products and provider, offering a broad
range of healthcare products and related services and operates two
private hospitals. For more information, please visit
www.usbimi.com.
Safe Harbor Statement
Certain matters discussed in this news release
are forward-looking statements that involve a number of risks and
uncertainties including, but not limited to, the Company’s ability
to achieve profitable operations, its ability to continue to
operate as a going concern, its ability to continue to meet NASDAQ
continued listing requirements, the effects of the spread of the
Coronavirus (COVID-19), the demand for the Company’s products and
services in the People’s Republic of China, general economic
conditions and other risk factors detailed in the Company’s annual
report and other filings with the United States Securities and
Exchange Commission.
Investor Relations Contact:
Janice Wang EverGreen Consulting Inc. Email:
IR@changqingconsulting.com Phone: +1 571-464-9470 (from
U.S.) +86 13811768559 (from China)
BOQI INTERNATIONAL MEDICAL, INC. AND ITS
SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
|
|
March 31 |
|
|
December 31 |
|
|
|
2021 |
|
|
2020 |
|
ASSETS |
|
|
|
|
|
|
CURRENT
ASSETS |
|
|
|
|
|
|
Cash |
|
$ |
2,830,834 |
|
|
$ |
135,309 |
|
Restricted cash |
|
|
4,590 |
|
|
|
- |
|
Accounts receivable, net |
|
|
7,169,691 |
|
|
|
6,686,552 |
|
Advances to suppliers |
|
|
3,093,935 |
|
|
|
2,693,325 |
|
Amount due from related parties |
|
|
41,012 |
|
|
|
- |
|
Inventories, net |
|
|
3,569,135 |
|
|
|
735,351 |
|
Prepayments and other receivables |
|
|
4,941,351 |
|
|
|
14,880,526 |
|
Operating lease-right of use assets |
|
|
46,521 |
|
|
|
53,425 |
|
Total current assets |
|
|
21,697,069 |
|
|
|
25,184,488 |
|
|
|
|
|
|
|
|
|
|
NON-CURRENT ASSETS |
|
|
|
|
|
|
|
|
Deferred tax assets |
|
|
181,451 |
|
|
|
193,211 |
|
Property, plant and equipment, net |
|
|
1,769,927 |
|
|
|
910,208 |
|
Operating lease-right of use assets |
|
|
1,572,515 |
|
|
|
- |
|
Intangible assets-net |
|
|
13,445 |
|
|
|
- |
|
Goodwill |
|
|
24,512,118 |
|
|
|
6,914,232 |
|
Total non-current assets |
|
|
28,049,456 |
|
|
|
8,017,651 |
|
|
|
|
|
|
|
|
|
|
TOTAL
ASSETS |
|
$ |
49,746,525 |
|
|
$ |
33,202,139 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND EQUITY |
|
|
|
|
|
|
|
|
CURRENT
LIABILITIES |
|
|
|
|
|
|
|
|
Short-term loans |
|
$ |
1,054,510 |
|
|
$ |
904,228 |
|
Long-term loans due within one year |
|
|
496,974 |
|
|
|
34,201 |
|
Convertible promissory notes, net |
|
|
5,132,530 |
|
|
|
3,328,447 |
|
Accounts payable, trade |
|
|
10,183,541 |
|
|
|
5,852,050 |
|
Advances from customers |
|
|
529,279 |
|
|
|
194,086 |
|
Amount due to related parties |
|
|
791,581 |
|
|
|
226,514 |
|
Taxes payable |
|
|
60,322 |
|
|
|
773,649 |
|
Other payables and accrued liabilities |
|
|
4,849,557 |
|
|
|
4,228,976 |
|
Lease liability-current |
|
|
354,705 |
|
|
|
23,063 |
|
Total current liabilities |
|
|
23,452,999 |
|
|
|
15,565,214 |
|
|
|
|
|
|
|
|
|
|
Lease liability-non current |
|
|
1,396,148 |
|
|
|
22,457 |
|
Long-term loans - non-current |
|
|
425,592 |
|
|
|
720,997 |
|
Total non-current liabilities |
|
|
1,821,740 |
|
|
|
743,454 |
|
|
|
|
|
|
|
|
|
|
TOTAL
LIABILITIES |
|
|
25,274,739 |
|
|
|
16,308,668 |
|
|
|
|
|
|
|
|
|
|
EQUITY |
|
|
|
|
|
|
|
|
Common stock, $0.001 par value; 50,000,000 shares authorized;
20,131,488 and 13,254,587 shares issued and outstanding as of March
31, 2021 and December 31, 2020, respectively |
|
|
20,131 |
|
|
|
13,254 |
|
Additional paid-in capital |
|
|
37,362,809 |
|
|
|
26,344,920 |
|
Statutory reserves |
|
|
2,263,857 |
|
|
|
2,263,857 |
|
Accumulated deficit |
|
|
(16,248,215 |
) |
|
|
(12,914,973 |
) |
Accumulated other comprehensive income |
|
|
853,795 |
|
|
|
1,003,392 |
|
Total BOQI International Medical Inc.’s equity |
|
|
24,252,377 |
|
|
|
16,710,450 |
|
|
|
|
|
|
|
|
|
|
NON-CONTROLLING INTERESTS |
|
|
219,409 |
|
|
|
183,021 |
|
|
|
|
|
|
|
|
|
|
Total equity |
|
|
24,471,786 |
|
|
|
16,893,471 |
|
|
|
|
|
|
|
|
|
|
Total liabilities and equity |
|
$ |
49,746,525 |
|
|
$ |
33,202,139 |
|
BOQI INTERNATIONAL MEDICAL, INC. AND ITS
SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE GAIN/LOSS (UNAUDITED)
|
|
For three months ended March 31 |
|
|
|
2021 |
|
|
2020 |
|
REVENUES |
|
|
2,168,004 |
|
|
|
414,584 |
|
|
|
|
|
|
|
|
|
|
COST
OF REVENUES |
|
|
1,575,743 |
|
|
|
332,299 |
|
|
|
|
|
|
|
|
|
|
GROSS
PROFIT(LOSS) |
|
|
592,261 |
|
|
|
82,285 |
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
Sales and marketing |
|
|
452,636 |
|
|
|
41,070 |
|
General and administrative |
|
|
3,380,014 |
|
|
|
1,364,952 |
|
Total
operating expenses |
|
|
3,832,650 |
|
|
|
1,406,022 |
|
|
|
|
|
|
|
|
|
|
LOSS
FROM OPERATIONS |
|
|
(3,240,389 |
) |
|
|
(1,323,737 |
) |
|
|
|
|
|
|
|
|
|
OTHER
INCOME (EXPENSE) |
|
|
|
|
|
|
|
|
Interest expense |
|
|
44,355 |
|
|
|
21,684 |
|
Other (income)/ expense |
|
|
(12,865 |
) |
|
|
545 |
|
Total
other income (expense), net |
|
|
(31,490 |
) |
|
|
(22,229 |
) |
|
|
|
|
|
|
|
|
|
LOSS
BEFORE INCOME TAXES |
|
|
(3,271,879 |
) |
|
|
(1,345,966 |
) |
|
|
|
|
|
|
|
|
|
PROVISION FOR INCOME TAXES |
|
|
18,748 |
|
|
|
1,268 |
|
|
|
|
|
|
|
|
|
|
NET
LOSS FROM CONTINUING OPERATIONS |
|
|
(3,290,627 |
) |
|
|
(1,347,234 |
) |
|
|
|
|
|
|
|
|
|
DISCONTINUED OPERATIONS |
|
|
|
|
|
|
|
|
Income/(loss) from operations of discontinued operations |
|
|
- |
|
|
|
(854,957 |
) |
|
|
|
|
|
|
|
|
|
NET
LOSS |
|
|
(3,290,627 |
) |
|
|
(2,202,191 |
) |
Less: net income (loss) attributable to non-controlling
interest |
|
|
42,615 |
|
|
|
(7,316 |
) |
NET
LOSS ATTRIBUTABLE TO BOQI INTERATIONAL MEDICAL INC. |
|
$ |
(3,333,242 |
) |
|
$ |
(2,194,875 |
) |
|
|
|
|
|
|
|
|
|
OTHER
COMPREHENSIVE LOSS |
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
|
|
(149,597 |
) |
|
|
(120,201 |
) |
|
|
|
|
|
|
|
|
|
TOTAL
COMPREHENSIVE LOSS |
|
|
(3,440,224 |
) |
|
|
(2,322,392 |
) |
Less: comprehensive loss attributable to non-controlling
interests |
|
|
(10,886 |
) |
|
|
(4,935 |
) |
COMPREHENSIVE LOSS ATTRIBUTABLE TO BOQI INTERNATIONAL MEDICAL
INC. |
|
$ |
(3,429,338 |
) |
|
$ |
(2,317,457 |
) |
|
|
|
|
|
|
|
|
|
WEIGHTED
AVERAGE NUMBER OF COMMON SHARES |
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
16,693,038 |
|
|
|
9,271,641 |
|
|
|
|
|
|
|
|
|
|
INCOME
(LOSS) PER SHARE |
|
|
|
|
|
|
|
|
Continuing operation-Basic and diluted |
|
$ |
(0.20 |
) |
|
$ |
(0.15 |
) |
Discontinued operation-Basic and diluted |
|
$ |
- |
|
|
$ |
(0.09 |
) |
Basic and diluted |
|
$ |
(0.20 |
) |
|
$ |
(0.24 |
) |
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Apr 2023 to Apr 2024